Intracellular Stock Analysis


USD 52.85  0.60  1.12%   

The modest gains experienced by current holders of Intracellular Th may raise some interest from stockholders. The stock closed today at a share price of 52.85 on 476,945 in trading volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.07. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Intracellular Th partners.
Please see Risk vs Return Analysis.
The Intracellular stock analysis report makes it easy to digest most publicly released information about Intracellular and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Intracellular Stock analysis module also helps to analyze the Intracellular price relationship with some important fundamental indicators such as market cap and management efficiency.

Intracellular Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.61. Intracellular Th had not issued any dividends in recent years. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people. To learn more about Intracellular Th call Sharon Mates at 646 440 9333 or check out

Intracellular Th Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Intracellular's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Intracellular Th or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Intracellular Th has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 83.8 M. Net Loss for the year was (284.13 M) with loss before overhead, payroll, taxes, and interest of (13.08 M).
Intracellular Th currently holds about 628.74 M in cash with (259.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64.
Intracellular Th has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company shares are owned by institutional investors
Latest headline from Best Value Health Care Supplies Stocks to Buy in 2022 - Best Stocks

Intracellular Th Upcoming and Recent Events

Earnings reports are used by Intracellular to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intracellular previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Intracellular Largest EPS Surprises

Earnings surprises can significantly impact Intracellular's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Intracellular SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Intracellular prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Intracellular investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Intracellular Th specific information freely available to individual and institutional investors to make a timely investment decision.
9th of August 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
13th of June 2022
Submission of Matters to a Vote of Security Holders
10th of May 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
25th of April 2022
Financial Statements and Exhibits. Other Events
21st of April 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
1st of March 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
10th of February 2022
Unclassified Corporate Event
9th of February 2022
Unclassified Corporate Event

Intracellular Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 5.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intracellular's market, we take the total number of its shares issued and multiply it by Intracellular's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Intracellular Profitablity

Intracellular's profitability indicators refer to fundamental financial ratios that showcase Intracellular's ability to generate income relative to its revenue or operating costs. If, let's say, Intracellular is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Intracellular's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Intracellular's profitability requires more research than a typical breakdown of Intracellular's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (1.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.61) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.02.
Last ReportedProjected for 2022
Return on Investment(53.16) (57.36) 
Return on Average Assets(47.07) (50.78) 
Return on Average Equity(52.87) (57.05) 
Return on Invested Capital(0.63) (0.65) 
Return on Sales(3.39) (3.66) 

Management Efficiency

The entity has return on total asset (ROA) of (0.2821) % which means that it has lost $0.2821 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.5084) %, meaning that it created substantial loss on money invested by shareholders. Intracellular management efficiency ratios could be used to measure how well intracellular th manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -57.36. The current Return on Average Assets is estimated to decrease to -50.78. Intracellular Asset Turnover is most likely to slightly decrease in the upcoming years. The last year's value of Asset Turnover was reported at 0.14. The current Tangible Assets Book Value per Share is estimated to increase to 6.98, while Total Assets are projected to decrease to roughly 387 M.
Last ReportedProjected for 2022
Book Value per Share 5.14  6.05 
Enterprise Value over EBIT(15.00) (16.18) 
Enterprise Value over EBITDA(14.75) (15.92) 
Price to Book Value 10.20  8.15 
Tangible Assets Book Value per Share 6.03  6.98 
Enterprise Value4.2 B4.5 B
Tangible Asset Value489.9 M435.4 M

Technical Drivers

As of the 2nd of December, Intracellular retains the Downside Deviation of 2.86, risk adjusted performance of 0.0954, and Market Risk Adjusted Performance of 0.224. Intracellular technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Intracellular Th, which can be compared to its competitors. Please check out Intracellular Th information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Intracellular is priced fairly, providing market reflects its last-minute price of 52.85 per share. Given that Intracellular Th has jensen alpha of 0.0806, we strongly advise you to confirm Intracellular Th's regular market performance to make sure the company can sustain itself at a future point.

Intracellular Th Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Triangular Moving Average shows Intracellular double smoothed mean price over a specified number of previous prices (i.e., averaged twice).

Intracellular Th Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intracellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intracellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intracellular insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Nostrand Robert L over a month ago via Macroaxis 
Acquisition by Van Nostrand Robert L of 110 shares of Intra-Cellular Ther subject to Rule 16b-3
Rory Riggs over a month ago via Macroaxis 
Acquisition by Rory Riggs of 365 shares of Intra-Cellular Ther subject to Rule 16b-3
Lawrence Hineline over two months ago via Macroaxis 
Exercise or conversion by Lawrence Hineline of 65164 shares of Intra-Cellular Ther subject to Rule 16b-3
Van Nostrand Robert L over three months ago via Macroaxis 
Acquisition by Van Nostrand Robert L of 108 shares of Intra-Cellular Ther subject to Rule 16b-3
Joel Marcus over six months ago via Macroaxis 
Exercise or conversion by Joel Marcus of 14189 shares of Intra-Cellular Ther subject to Rule 16b-3
Michael Halstead over six months ago via Macroaxis 
Exercise or conversion by Michael Halstead of 111 shares of Intra-Cellular Ther subject to Rule 16b-3
Salas Eduardo Rene over six months ago via Macroaxis 
Acquisition by Salas Eduardo Rene of 20000 shares of Intra-Cellular Ther subject to Rule 16b-3
Rory Riggs over six months ago via Macroaxis 
Sale by Rory Riggs of 20686 shares of Intra-Cellular Ther
Mark Neumann over six months ago via Macroaxis 
Exercise or conversion by Mark Neumann of 86348 shares of Intra-Cellular Ther subject to Rule 16b-3
Rory Riggs over six months ago via Macroaxis 
Sale by Rory Riggs of 15736 shares of Intra-Cellular Ther
Suresh Durgam over six months ago via Macroaxis 
Acquisition by Suresh Durgam of 22034 shares of Intra-Cellular Ther subject to Rule 16b-3
Sharon Mates over six months ago via Macroaxis 
Exercise or conversion by Sharon Mates of 38925 shares of Intra-Cellular Ther subject to Rule 16b-3

Intracellular Technical and Predictive Indicators

Intracellular Forecast Models

Intracellular time-series forecasting models is one of many Intracellular's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intracellular's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Intracellular Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Intracellular prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intracellular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Intracellular. By using and applying Intracellular Stock analysis, traders can create a robust methodology for identifying Intracellular entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 42.74  42.49 
EBITDA Margin 43.47  43.22 
Gross Margin 90.41  100.30 
Profit Margin 42.73  42.48 

Current Intracellular Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intracellular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intracellular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Intracellular Th current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Intracellular analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Intracellular stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Intracellular Th, talking to its executives and customers, or listening to Intracellular conference calls.
Intracellular Analyst Advice Details

Intracellular Stock Analysis Indicators

Intracellular Th stock analysis indicators help investors evaluate how Intracellular stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Intracellular shares will generate the highest return on investment. By understating and applying Intracellular stock analysis, traders can identify Intracellular position entry and exit signals to maximize returns.
Begin Period Cash Flow61445933.00
Common Stock Shares Outstanding81253394.00
Total Stockholder Equity417890675.00
Total Cashflows From Investing Activities280343631.00
Tax Provision5631.00
Property Plant And Equipment Net22555182.00
Retained Earnings-1221229698.00
Cash And Short Term Investments412333338.00
Retained Earnings Total Equity-1221229698.00
Accounts Payable8691220.00
Net Debt-92364990.00
50 Day M A48.1674
Total Current Liabilities53356478.00
Currency CodeUSD
Other Operating Expenses377525731.00
Non Current Assets Total22641266.00
Common Stock Total Equity8189.00
Non Currrent Assets Other86084.00
Please see Risk vs Return Analysis. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Intracellular Stock analysis

When running Intracellular Th price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Equity Valuation
Check real value of public entities based on technical and fundamental data
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Transaction History
View history of all your transactions and understand their impact on performance
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.1 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine Intracellular value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.